Trial Profile

A Phase I, First-in-human, Randomised, Double-blind, Placebo-controlled, Single Ascending Oral Dose, Safety, Tolerability and Pharmacokinetic Study to Investigate the Effects of OCT461201 in Healthy Volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 03 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AAT 730 (Primary)
Indications Irritable bowel syndrome; Neuropathic pain; Postherpetic neuralgia; Visceral pain
Focus Adverse reactions; First in man
Sponsors Octavian Therapeutics; Oxford Cannabinoid Technologies

11 Feb 2025 According to Octavian Therapeutics media release, Oxford Cannabinoid Technologies is now called Octavian Therapeutics
08 May 2024 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com